The novel nonstimulant medication from Supernus Pharmaceuticals can be sprinkled on food.
FDA approved viloxazine extended-release capsules (Qelbree, Supernus Pharmaceuticals), its first drug approval for children with attention-deficit hyperactivity disorder (ADHD) in more than a decade.
Jack Khattar
The sprinkleable non-stimulant medication is indicated for pediatric patients 6 to 17 years old. “Capsules can be opened and sprinkled on a teaspoonful of applesauce or swallowed whole. This makes it easier for patients — like a young child — who might have difficulty swallowing a capsule whole,” Jack Khattar, president and CEO of Supernus, told FormularyWatch®.
Related: FDA clears first non-drug option to treat ADHD in children
Based on the efficacy demonstrated in Supernus’s clinical trials, “We believe Qelbree offers a unique new alternative for the treatment of ADHD,” Khattar said in a press release issued on April 2. “Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.”
Khattar expects Qelbree to be available this quarter but declined to reveal the drug’s wholesale acquisition cost. “Supernus doesn’t comment on pricing of new products before they are launched,” Khattar said, adding that Qelbree will be priced comparably to other ADHD products in the market. “We plan to have a robust patient access program available at launch, including a copay assistance program,” Khattar said.
Related: FDA approves Ponvoy, once-a-day oral drug for MS
Qelbree’s approval in based on data from an extensive development program consisting of four Phase 3 clinical trials that studied more than 1,000 pediatric patients, ages 6 to 17.
In December, Supernus announced positive results from a Phase 3 trial in adult patients with ADHD and plans to submit a supplemental New Drug Application to the FDA for Qelbree in adults in the second half of 2021.
Qelbree may increase suicidal thoughts and actions in some children with ADHD — especially within the first few months of treatment or when the dose is changed, Supernus said. Qelbree is also contraindicated for patients who also take certain antidepression medicines— especially monoamine oxidase inhibitors — or certain asthma medicines.
Read more: FDA clears first generic treatment for severe hypoglycemia
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More